No MSC or stem cell therapy is FDA-approved for ulcerative colitis. An allogeneic MSC product (darvadstrocel) is approved in the EU for complex perianal Crohn's fistulae, a related but distinct IBD indication. This precedent demonstrates regulatory feasibility for MSCs in IBD but does not extend to UC without separate clinical evidence. Clinics offering UC-targeted stem cell treatments operate outside formal regulatory pathways in most jurisdictions.
Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum, characterised by bloody diarrhoea, urgency, abdominal pain, and systemic complications including anaemia and extraintestinal manifestations. Modern management combines 5-aminosalicylate agents, immunosuppression, and biologic therapies; however, a significant proportion of patients experience relapsing disease or intolerance to standard drugs. Mesenchymal stem cell research in UC explores whether cell-derived immunomodulatory factors might suppress mucosal inflammation and promote tissue healing. Related approved therapies (such as an MSC product indicated for perianal Crohn's fistulae) provide mechanistic precedent, though this distinct indication remains investigational in UC.
Sunt un candidat? → · Ulcerative Colitis: full overview → · Cost Colită Ulcerativă → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită